RE:Worth notingThat was another point mr. T. was mentioning!!!
Soon, very soon !!!! = the answer about my Q.: any news on the IR person ??
SPCEO1 - (2/21/2020 11:07:00 AM) Worth noting I ahve been meaning to point out that TH has talked openly about starting a phase III trial even though they are still in discussions with the FDA about it. Therefore, they are clearly confident about there being a phase IIIor they would not be putting that at risk by talking about it and potentially ticking off the FDA.
Now, while a phase III will be an important step forward, the cost of the trial and the endpoints will determine how interested the market is in it and we don't know any of that yet. But it is encouraging that TH has talked about starting the phase III later this year. It suggests the chance of the FDA responding that there is no point in TH proceeding with a phase III are near zero, so we can pretty much eliminate that option. It also reduces the possibility that the FDA has given feedback that would indicate the phase III endppoint costs or endpoints are likely to be so onerous that the TH board would just decide it is not worth proceeding with the phase III.
Now, at this point I am not sure there are many people other than those reading this board that are focused on the phase III opportunity. So, if they came out with really good news on this front tomorrow, I am not sure how jubilantly the market would react since I don't get the impression that many are anxiously waiting to hear this news. Hopefully, I am wrong about that and I could well be. But the sooner they get an IR perosn on staff and working on building such anticipation, the better.
On the negative side of the equation, the fact they have not yet hired an IR person may indicate the news we are looking for is not going to be as good as we had hoped or is going to be delayed in some way. One has to assume that if TH was fully confident in their position, they would have that IR person on staff already. Hopefully, alot of things will become much clearer on Tuesday.